Market Overview

UPDATE: Bank of America Upgrades Celgene to Buy on Improving Growth Outlook

Related CELG
#PreMarket Primer: Thursday, August 14: Investors Are Unfazed By Weak Retail Sales
Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

Bank of America upgraded Celgene Corporation (NASDAQ: CELG) from Neutral to Buy and raised the price target from $88.00 to $115.00.

Bank of America commented, "We are upgrading CELG from Neutral to Buy and increasing our PO from $88 to $115 (16x2014E) following a series of model changes that show CELG should grow sales by a minimum of 14% and EPS by 25% CAGR over the next 5 yrs. We have increased conviction in CELG's long term growth profile driven by multiple growth products, and believe shares will continue to experience PE expansion over 2013 driven by: (1) positive Abraxane data (Jan 24-26), (2) better Pomalyst pricing and product launch vs. Street consensus, and (3) visibility on CELG's emerging pipeline, incl novel imids with potential positive Revlimid life cycle implications."

Celgene closed at $97.67 on Monday.

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters